HALIFAX, April 13, 2015 /CNW/ - MedMira Inc.
(TSXV: MIR) announced today that the Company's Board of
Directors and Corporate Secretary have been granted options to
purchase common shares under its Stock Option Plan which was
approved by shareholders at the Company's Annual General and
Special Meeting on January 25,
2013. Mr. Marvyn Robar, Mr.
Hermes Chan, Dr. Colin MacGillivray, Mr. Romano Robusto, Dr. Michael Sidler and Ms. Robyn Cook were granted a total of 1,021,875
options at an exercise price of $0.10
per share and exercisable for a period of three years ending
April 12, 2018.
About MedMira
MedMira is a leading developer and manufacturer of vertical flow
rapid diagnostics. The Company's tests provide hospitals, labs,
clinics and individuals with instant diagnosis for diseases such as
HIV and hepatitis C in just three easy steps. The Company's tests
are sold under the Revealâ, Multiplo™ and Miriad™ brands in global
markets. Based on its patented Rapid Vertical Flow Technologyä,
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada,
the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada. For
more information visit medmira.com. Follow us on Twitter and
LinkedIn.
This news release contains forward-looking statements, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible approval and launch of new products, future growth, and
new business opportunities. Actual events could materially
differ from those projected herein and depend on a number of
factors including, but not limited to, changing market conditions,
successful and timely completion of clinical studies, uncertainties
related to the regulatory approval process, establishment of
corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
SOURCE MedMira Inc.